Leaked internal emails appear to show employees at one of the world’s leading pharmaceutical companies calling for “celebration” over price hikes of cancer drugs, an investigation has revealed.
Staff at Aspen Pharmacare reportedly plotted to destroy stocks of life-saving medicines during a price dispute with the Spanish health service in 2014.
After purchasing five different cancer drugs from British firm GlaxoSmithKline (GSK), the company tried to sell the medicines in Europe for up to 40 times their previous price, reported The Times.
In 2013, the price of one pack of a chemotherapy drug called busulfan, used to treat leukaemia, rose from £5.20 to £65.22 in England and Wales, according to the newspaper.
The other four drugs, including leukeran, also used by leukaemia patients, and melphalan, for skin and ovarian cancers, also became up to four times more expensive. Full story...
Related posts:
Staff at Aspen Pharmacare reportedly plotted to destroy stocks of life-saving medicines during a price dispute with the Spanish health service in 2014.
After purchasing five different cancer drugs from British firm GlaxoSmithKline (GSK), the company tried to sell the medicines in Europe for up to 40 times their previous price, reported The Times.
In 2013, the price of one pack of a chemotherapy drug called busulfan, used to treat leukaemia, rose from £5.20 to £65.22 in England and Wales, according to the newspaper.
The other four drugs, including leukeran, also used by leukaemia patients, and melphalan, for skin and ovarian cancers, also became up to four times more expensive. Full story...
Related posts:
- The cancer industry is too prosperous to allow a cure...
- Why are there so many cancers now?
- The cancer industry: failure, lies and big profits...
- Making a killing with cancer: a 124.6 billion dollar industry...
- Why medecine won't allow cancer to be cured...
- Cancer: why the profiteers don't want a cure...
- “Most cancer research is largely a fraud”
No comments:
Post a Comment